publication . Article . 2014

Designing vaccines for the twenty-first century society.

Oretta Finco; Rino Rappuoli;
Open Access English
  • Published: 23 Jan 2014 Journal: Frontiers in Immunology (issn: 1664-3224, Copyright policy)
  • Publisher: Frontiers Media S.A.
Abstract
The history of vaccination clearly demonstrates that vaccines have been highly successful in preventing infectious diseases, reducing significantly the incidence of childhood diseases and mortality. However, many infections are still not preventable with the currently available vaccines and they represent a major cause of mortality worldwide. In the twenty-first century, the innovation brought by novel technologies in antigen discovery and formulation together with a deeper knowledge of the human immune responses are paving the way for the development of new vaccines. Final goal will be to rationally design effective vaccines where conventional approaches have f...
Subjects
free text keywords: Vaccination, Technologies, glycoconjugate, Vaccine Design, structural vaccinology, Immunologic diseases. Allergy, RC581-607, Immunology, Mini Review, glyco-conjugate, Twenty-First Century, Medicine, business.industry, business, Immune system, Antigen, Intensive care medicine, medicine.medical_specialty
Related Organizations
68 references, page 1 of 5

1 Willis NJ. Edward Jenner and the eradication of smallpox. Scott Med J (1997) 42:118–21.

2 Lakhani S. Early clinical pathologists: Edward Jenner (1749-1823). J Clin Pathol (1992) 45:756–8.10.1136/jcp.45.9.756 [OpenAIRE] [DOI]

3 Kaushik DK Sehgal D. Developing antibacterial vaccines in genomics and proteomics era. Scand J Immunol (2008) 67:544–52.10.1111/j.1365-3083.2008.02107.x 18397199 [OpenAIRE] [PubMed] [DOI]

4 Rappuoli R Miller HI Falkow S. Medicine. The intangible value of vaccination. Science (2002) 297:937–9.10.1126/science.1075173 [OpenAIRE] [DOI]

5 Plotkin SA. Vaccines: past, present and future. Nat Med (2005) 11:S5–11.10.1038/nm1209 15812490 [OpenAIRE] [PubMed] [DOI]

6 Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med (2004) 10:1177–85.10.1038/nm1129 15516917 [OpenAIRE] [PubMed] [DOI]

7 Makela PH Peltola H Kayhty H Jousimies H Pettay O Ruoslahti E Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 136(Suppl):S43–50.10.1093/infdis/136.Supplement.S43 [OpenAIRE] [DOI]

8 Peltola H Makela H Kayhty H Jousimies H Herva E Hallstrom K Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med (1977) 297:686–91.10.1056/NEJM197709292971302 408682 [OpenAIRE] [PubMed] [DOI]

9 Lesinski GB Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods (2001) 47:135–49.10.1016/S0167-7012(01)00290-1 11576678 [PubMed] [DOI]

10 Conaty S Watson L Dinnes J Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine (2004) 22:3214–24.10.1016/j.vaccine.2003.08.050 15297076 [OpenAIRE] [PubMed] [DOI]

11 Lepow ML Goldschneider I Gold R Randolph M Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 60:673–80.411104 [PubMed]

12 Peltola H Kayhty H Virtanen M Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med (1984) 310:1561–6.10.1056/NEJM198406143102404 6610125 [OpenAIRE] [PubMed] [DOI]

13 Makela PH Kayhty H. Evolution of conjugate vaccines. Expert Rev Vaccines (2002) 1:399–410.10.1586/14760584.1.3.399 [OpenAIRE] [DOI]

14 Lai Z Schreiber JR. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine (2009) 27:3137–44.10.1016/j.vaccine.2009.03.064 19446183 [OpenAIRE] [PubMed] [DOI]

15 Smith KG Light A Nossal GJ Tarlinton DM. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J (1997) 16:2996–3006.10.1093/emboj/16.11.2996 9214617 [OpenAIRE] [PubMed] [DOI]

68 references, page 1 of 5
Abstract
The history of vaccination clearly demonstrates that vaccines have been highly successful in preventing infectious diseases, reducing significantly the incidence of childhood diseases and mortality. However, many infections are still not preventable with the currently available vaccines and they represent a major cause of mortality worldwide. In the twenty-first century, the innovation brought by novel technologies in antigen discovery and formulation together with a deeper knowledge of the human immune responses are paving the way for the development of new vaccines. Final goal will be to rationally design effective vaccines where conventional approaches have f...
Subjects
free text keywords: Vaccination, Technologies, glycoconjugate, Vaccine Design, structural vaccinology, Immunologic diseases. Allergy, RC581-607, Immunology, Mini Review, glyco-conjugate, Twenty-First Century, Medicine, business.industry, business, Immune system, Antigen, Intensive care medicine, medicine.medical_specialty
Related Organizations
68 references, page 1 of 5

1 Willis NJ. Edward Jenner and the eradication of smallpox. Scott Med J (1997) 42:118–21.

2 Lakhani S. Early clinical pathologists: Edward Jenner (1749-1823). J Clin Pathol (1992) 45:756–8.10.1136/jcp.45.9.756 [OpenAIRE] [DOI]

3 Kaushik DK Sehgal D. Developing antibacterial vaccines in genomics and proteomics era. Scand J Immunol (2008) 67:544–52.10.1111/j.1365-3083.2008.02107.x 18397199 [OpenAIRE] [PubMed] [DOI]

4 Rappuoli R Miller HI Falkow S. Medicine. The intangible value of vaccination. Science (2002) 297:937–9.10.1126/science.1075173 [OpenAIRE] [DOI]

5 Plotkin SA. Vaccines: past, present and future. Nat Med (2005) 11:S5–11.10.1038/nm1209 15812490 [OpenAIRE] [PubMed] [DOI]

6 Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med (2004) 10:1177–85.10.1038/nm1129 15516917 [OpenAIRE] [PubMed] [DOI]

7 Makela PH Peltola H Kayhty H Jousimies H Pettay O Ruoslahti E Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 136(Suppl):S43–50.10.1093/infdis/136.Supplement.S43 [OpenAIRE] [DOI]

8 Peltola H Makela H Kayhty H Jousimies H Herva E Hallstrom K Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med (1977) 297:686–91.10.1056/NEJM197709292971302 408682 [OpenAIRE] [PubMed] [DOI]

9 Lesinski GB Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods (2001) 47:135–49.10.1016/S0167-7012(01)00290-1 11576678 [PubMed] [DOI]

10 Conaty S Watson L Dinnes J Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine (2004) 22:3214–24.10.1016/j.vaccine.2003.08.050 15297076 [OpenAIRE] [PubMed] [DOI]

11 Lepow ML Goldschneider I Gold R Randolph M Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 60:673–80.411104 [PubMed]

12 Peltola H Kayhty H Virtanen M Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med (1984) 310:1561–6.10.1056/NEJM198406143102404 6610125 [OpenAIRE] [PubMed] [DOI]

13 Makela PH Kayhty H. Evolution of conjugate vaccines. Expert Rev Vaccines (2002) 1:399–410.10.1586/14760584.1.3.399 [OpenAIRE] [DOI]

14 Lai Z Schreiber JR. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine (2009) 27:3137–44.10.1016/j.vaccine.2009.03.064 19446183 [OpenAIRE] [PubMed] [DOI]

15 Smith KG Light A Nossal GJ Tarlinton DM. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. EMBO J (1997) 16:2996–3006.10.1093/emboj/16.11.2996 9214617 [OpenAIRE] [PubMed] [DOI]

68 references, page 1 of 5
Any information missing or wrong?Report an Issue